Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06908707 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

A Phase 1 study, sponsored by Laekna Limited.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT06908707: Completed Phase 1 study, sponsored by Laekna Limited.

NCT06908707 is a Phase 1 study that has completed, run by Laekna Limited. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06908707, a Phase 1 study, has completed, sponsored by Laekna Limited.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women

Primary Outcome

Number of participants with SAEs \- Evaluation of Safety and Tolerability of LAE102

Interventions

  • DRUG Placebo IV
  • DRUG Placebo SC
  • DRUG LAE102 SC
  • DRUG LAE102 IV

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-04-22
Est. Completion 2025-10-23
Phase Phase 1
Laekna Limited

4 total trials

What the finished NCT06908707 record still lists

NCT06908707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo IV is the first listed.

NCT06908707 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06908707 about?

NCT06908707 is a clinical study titled "A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women". The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women

What is the current status of trial NCT06908707?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-04-22. Estimated completion is 2025-10-23.

What interventions are being tested in trial NCT06908707?

The interventions under investigation include: Placebo IV (DRUG), Placebo SC (DRUG), LAE102 SC (DRUG), LAE102 IV (DRUG).

Who is sponsoring clinical trial NCT06908707?

This trial is sponsored by Laekna Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06908707's enrollment target sits among peer trials

32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06908707, the US trial registry maintained by the National Library of Medicine. NCT06908707 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.